EIF4A3 shRNA慢病毒载体的构建及其稳定转染细胞系的建立

doi:10.13481/j.1671-587X.20240330

摘要/Abstract

摘要：

目的构建真核细胞翻译起始因子4A3（EIF4A3）-短发夹RNA（shRNA）慢病毒载体，建立Neuro-2a-EIF4A3-shRNA稳定转染细胞系。方法通过美国国家生物技术信息中心（NCBI）数据库检索EIF4A3基因序列，设计并合成PCR鉴定引物，并将其连接至经EcoR Ⅰ和Age Ⅰ酶切的慢病毒GV493载体，构建GV493-EIF4A3-shRNA慢病毒质粒，PCR筛选阳性克隆并测序鉴定。将GV493空载质粒和GV493-EIF4A3-shRNA重组质粒分别转染至HEK293T细胞中，分别为GV493对照慢病毒和GV493-EIF4A3-shRNA慢病毒，转染48 h后收集慢病毒进行包装并测定病毒滴度。将Neuro-2a细胞分为空白组、GV493对照组和GV493-EIF4A3 shRNA组，空白组不作处理，GV493对照组和GV493-EIF4A3 shRNA组分别采用相应慢病毒感染Neuro-2a细胞，慢病毒感染复数（MOI）为100，使用10 mg·L^－1嘌呤霉素筛选成功感染慢病毒的Neuro-2a细胞，荧光显微镜观察各组Neuro-2a细胞的生长状态和绿色荧光表达情况；实时荧光定量PCR（RT-qPCR）法和Western blotting法检测各组Neuro-2a细胞中EIF4A3 mRNA及蛋白表达水平。结果 PCR测序结果显示GV493-EIF4A3-shRNA重组质粒基因序列与设计合成的EIF4A3-shRNA序列一致，成功构建GV493-EIF4A3慢病毒载体。荧光显微镜观察可见HEK293T细胞荧光表达强烈，生长状态良好，慢病毒包装成功。GV493-对照慢病毒和GV493-EIF4A3-shRNA慢病毒的滴度均为2×10⁸TU·mL^－1，GV493对照组和GV493-EIF4A3 shRNA组Neuro-2a细胞生长状态良好且表达绿色荧光，表明慢病毒感染稳定细胞系构建成功。RT-qPCR法，与空白组和GV493对照组比较，GV493-EIF4A3 shRNA组Neuro-2a细胞EIF4A3 mRNA表达水平明显降低（P<0.01）。Western blotting法，各组在相对分子质量49 000处出现特异性条带，提示Neuro-2a细胞中EIF4A3蛋白表达成功；与空白组和GV493对照组比较，GV493-EIF4A3 shRNA组Neuro-2a细胞中EIF4A3蛋白表达水平明显降低（P<0.01）。结论成功构建GV493-EIF4A3-shRNA慢病毒载体，建立了Neuro-2a-EIF4A3-shRNA稳定转染细胞系，为EIF4A3在颅内动脉粥样硬化的作用机制研究提供了参考。

关键词: 真核细胞翻译起始因子4A3, 短发夹RNA, 慢病毒, 稳定转染细胞系, Neuro-2a细胞

Abstract:

Objective To construct the eukaryotic cell translation initiation factor 4A3 （EIF4A3） short hairpin RNA （shRNA） lentiviral vector， and to establish the Neuro-2a-EIF4A3-shRNA stable transfection cell line. Methods The EIF4A3 gene sequence was retrieved from the National Center for Biotechnology Information （NCBI） database； the PCR identification primers were designed and synthesized， and connected to the lentiviral GV493 vector digested with EcoR I and Age I enzymes to construct the GV493-EIF4A3-shRNA lentiviral plasmid； PCR method was used to screen the positive clones， which were sequenced for the identification； the GV493 empty plasmid and GV493-EIF4A3-shRNA recombinant plasmid were transfected into the HEK293T cells， regarded as GV493 control lentivirus and GV493-EIF4A3-shRNA lentivirus， respectively. After 48 h of transfection， the lentiviruses were collected for packaging and the viral titer was determined. The Neuro-2a cells were divided into blank group， GV493 control group， and GV493-EIF4A3 shRNA group. The Neuro-2a cells in blank group were untreated， and the Neuro-2a cells in GV493 control group and GV493-EIF4A3 shRNA group were infected with the respective lentiviruses at a multiplicity of infection （MOI） of 100.The infected Neuro-2a cells were selected by 10 mg·L^-1 puromycin， and the growth status and green fluorescence expression of the Neuro-2a cells in various groups were observed under fluorescence microscope； real-time fluorescence quantitative PCR （RT-qPCR） and Western blotting methods were used to detect the expression levels of EIF4A3 mRNA and protein in the Neuro-2a cells in various groups. Results The PCR sequencing results showed that the gene sequence of the GV493-EIF4A3-shRNA recombinant plasmid was consistent with the designed EIF4A3-shRNA sequence， indicating successful construction of the GV493-EIF4A3 lentiviral vector. The fluorescence microscope observation results showed that there was strong fluorescence expression and good growth status in the HEK293T cells， confirming successful lentiviral packaging. The viral titers for GV493 control lentivirus and GV493-EIF4A3-shRNA lentivirus both were 2×10⁸ TU·mL^-1. The growth status of the Neuro-2a cells in GV493 control group and GV493-EIF4A3 shRNA group was good， and they expressed green fluorescence， indicating successful construction of the stable transfection cell line. The RT-qPCR results showed that compared with blank group and GV493 control group， the expression level of EIF4A3 mRNA in the cells in GV493-EIF4A3 shRNA group was significantly decreased （P<0.01）. The Western blotting results showed that the specific bands was at a relative molecular mass of 49 000， indicating successful EIF4A3 protein expression in the Neuro-2a cells. Compared with blank group and GV493 control group， the expression level of EIF4A3 protein in the cells in GV493-EIF4A3 shRNA group was significantly decreased （P<0.01）. Conclusion The GV493-EIF4A3-shRNA lentiviral vector is succfssfully constructed， and the Neuro-2a-EIF4A3-shRNA stable transfection cell line is established； the results provide the reference for the study of the effect of EIF4A3 on the intracranial atherosclerosis.

Key words: Eukaryotic translation initiation factor 4A3, Short hairpin RNA, Lentivirus, Stable transfection cell line, Neuro-2a cell

中图分类号:

R392

何嘉文,李友,廖科棋,李胜男. EIF4A3 shRNA慢病毒载体的构建及其稳定转染细胞系的建立[J]. 吉林大学学报(医学版), 2024, 50(3): 831-839.

Jiawen HE,You LI,Keqi LIAO,Shengnan LI. Construction of EIF4A3 shRNA lentiviral vector and establishment of its stable transfection cell line[J]. Journal of Jilin University(Medicine Edition), 2024, 50(3): 831-839.

图/表 6

图1

图2

图3

图4

图5

图6

参考文献 20

1	MCMAHON J J， MILLER E E， SILVER D L. The exon junction complex in neural development and neurodevelopmental disease［J］. Int J Dev Neurosci， 2016， 55： 117-123.
2	MAZLOOMIAN A， ARAKI S， OHORI M， et al. Pharmacological systems analysis defines EIF4A3 functions in cell-cycle and RNA stress granule formation［J］. Commun Biol， 2019， 2： 165.
3	FERRAIUOLO M A， LEE C S， LER L W， et al. A nuclear translation-like factor eIF4AⅢ is recruited to the mRNA during splicing and functions in nonsense-mediated decay［J］. Proc Natl Acad Sci U S A， 2004， 101（12）： 4118-4123.
4	FUKAO A， MISHIMA Y， TAKIZAWA N， et al. MicroRNAs trigger dissociation of eIF4AⅠ and eIF4AⅡ from target mRNAs in humans［J］. Mol Cell， 2014， 56（1）： 79-89.
5	GALICIA-VÁZQUEZ G， CHU J， PELLETIER J. eIF4AⅡ is dispensable for miRNA-mediated gene silencing［J］. RNA， 2015， 21（10）： 1826-1833.
6	WEI Y T， LU C F， ZHOU P， et al. EIF4A3-induced circular RNA ASAP1 promotes tumorigenesis and temozolomide resistance of glioblastoma via NRAS/MEK1/ERK1-2 signaling［J］. Neuro Oncol， 2021， 23（4）： 611-624.
7	YANG C J， HAWKINS K E， DORÉ S， et al. Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke［J］. Am J Physiol Cell Physiol， 2019， 316（2）： C135-C153.
8	LIU Y C， SONG J， ZHANG H W， et al. EIF4A3-induced circTOLLIP promotes the progression of hepatocellular carcinoma via the miR-516a-5p/PBX3/EMT pathway［J］. J Exp Clin Cancer Res， 2022， 41（1）： 164.
9	ZHANG S X， LENG T Y， ZHANG Q， et al. Sanguinarine inhibits epithelial ovarian cancer development via regulating long non-coding RNA CASC2-EIF4A3 axis and/or inhibiting NF-κB signaling or PI3K/AKT/mTOR pathway［J］. Biomed Pharmacother， 2018， 102： 302-308.
10	SUI X Z， WANG Y C， LIU H. hsa_circ_0101119 facilitates the progression of cervical cancer via an interaction with EIF4A3 to inhibit TCEAL6 expression［J］. Mol Med Rep， 2021， 24（3）： 654.
11	LAFFONT I， TAKAHASHI M， SHIBUKAWA Y， et al. Apolipoprotein E activates Akt pathway in neuro-2a in an isoform-specific manner［J］. Biochem Biophys Res Commun， 2002， 292（1）： 83-87.
12	LI Y S， REN S H， XIA J W， et al. EIF4A3-induced circ-BNIP3 aggravated hypoxia-induced injury of H9c2 cells by targeting miR-27a-3p/BNIP3［J］. Mol Ther Nucleic Acids， 2020， 19： 533-545.
13	YU F P， ZHANG Y， WANG Z Z， et al. Hsa_circ_0030042 regulates abnormal autophagy and protects atherosclerotic plaque stability by targeting eIF4A3［J］. Theranostics， 2021， 11（11）： 5404-5417.
14	ZHANG M， ZHU Y Q， ZHU J， et al. circ_0086296 induced atherosclerotic lesions via the IFIT1/STAT1 feedback loop by sponging miR-576-3p［J］. Cell Mol Biol Lett， 2022， 27（1）： 80.
15	RITZ K， DENSWIL N P， STAM O C G， et al. Cause and mechanisms of intracranial atherosclerosis［J］. Circulation， 2014， 130（16）： 1407-1414.
16	WANG Y， MENG R， LIU G， et al. Intracranial atherosclerotic disease［J］. Neurobiol Dis， 2019， 124： 118-132.
17	XU S K， GE Y S， WANG X B， et al. Circ-USP9X interacts with EIF4A3 to promote endothelial cell pyroptosis by regulating GSDMD stability in atherosclerosis［J］. Clin Exp Hypertens， 2023， 45（1）： 2186319.
18	YANG H Z， YANG W C， DAI W Q， et al. LINC00667 promotes the proliferation， migration， and pathological angiogenesis in non-small cell lung cancer through stabilizing VEGFA by EIF4A3［J］. Cell Biol Int， 2020， 44（8）： 1671-1680.
19	LAM M， SANOSAKA T， LUNDIN A， et al. Single-cell study of neural stem cells derived from human iPSCs reveals distinct progenitor populations with neurogenic and gliogenic potential［J］. Genes Cells， 2019， 24（12）： 836-847.
20	MATSUI T K， TSURU Y， HASEGAWA K， et al. Vascularization of human brain organoids［J］. Stem Cells， 2021， 39（8）： 1017-1024.

[1]	黄少婷,李友,吴钊淳,何嘉文,廖科棋,李胜男. SOX17过表达慢病毒载体和稳定转染细胞系的构建[J]. 吉林大学学报(医学版), 2023, 49(6): 1424-1430.
[2]	穆业腾,郭冲,胡楠楠,杨馥旭,薛晗,范宇鑫,郭峰霖,关新刚. 免疫检查点TIGIT慢病毒表达载体的构建和稳定表达TIGIT细胞系的建立[J]. 吉林大学学报(医学版), 2022, 48(5): 1341-1347.
[3]	刘宇轩,黄莉莉,杨馥旭,方楷漪,胡楠楠,穆业腾,郭冲,夏薇,关新刚. LAG3慢病毒质粒构建及其稳定转染细胞系的建立[J]. 吉林大学学报(医学版), 2022, 48(1): 136-141.
[4]	巩培, 刘竟然, 赵世敏, 王玉珍, 谢基明. MCM10沉默对乳腺癌MDA-MB-231细胞的增殖抑制作用及其机制[J]. 吉林大学学报(医学版), 2021, 47(3): 652-659.
[5]	徐宠俊,何荷蕃,林群,章涛. 人肝细胞生长因子基因慢病毒载体的构建及其在骨髓间充质干细胞中的表达[J]. 吉林大学学报(医学版), 2021, 47(1): 16-24.
[6]	陈少凤, 李胜男, 邓福, 朱佩仪, 李友. RHBDF2基因过表达慢病毒载体的构建和稳定表达RHBDF2细胞系的建立[J]. 吉林大学学报(医学版), 2020, 46(03): 444-450.
[7]	李胜男, 陈吴海, 陈少凤, 邓福, 朱佩仪, 李友. RHBDF2-shRNA慢病毒载体的构建和Neuro-2a-RHBDF2-shRNA稳转细胞系的建立[J]. 吉林大学学报(医学版), 2019, 45(06): 1224-1230.
[8]	李胜男, 王梦旭, 胡伟东, 陈少凤, 陈杏兰, 李友. miR-186过表达慢病毒载体的构建及鉴定[J]. 吉林大学学报(医学版), 2019, 45(05): 997-1002.
[9]	梁春梅, 许旭三, 余华军, 周霞, 温霞, 李友, KOJIC Snezana, 汪亚君, 马国达. 含心脏阿霉素反应蛋白基因的重组慢病毒过表达和RNA干扰载体的构建及鉴定[J]. 吉林大学学报(医学版), 2019, 45(04): 766-771.
[10]	王梦旭, 李胜男, 胡伟东, 陈少凤, 陈杏兰, 李友. miR-186海绵载体的构建及其在EA.hy926细胞株中的表达[J]. 吉林大学学报(医学版), 2019, 45(03): 498-503.
[11]	朱广伟, 黄金胜, 黄永建, 郑炜, 杨树钢, 林春霖, 陈恒恺, 叶建新. 内质网蛋白29过表达慢病毒载体的构建及其对胃癌细胞生物学行为的影响[J]. 吉林大学学报(医学版), 2019, 45(02): 244-250.
[12]	陈炳鹏, 任明, 李容杭, 韩青, 王金成. 基因芯片技术检测NOB1对骨肉瘤细胞相关基因的调控作用[J]. 吉林大学学报(医学版), 2018, 44(05): 929-934.
[13]	律东, 梁春梅, 李明颖, 殷静雯, 罗旭东, 林举达, 马国达. miR-137过表达慢病毒的包装和鉴定[J]. 吉林大学学报(医学版), 2017, 43(04): 694-697.
[14]	杨耀群, 谢淑丽, 吕国悦, 马强, 李开良, 王广义. 肝癌SMMC7721细胞株P27RF-Rho mRNA基因沉默对5-Fu药物敏感性的影响[J]. 吉林大学学报(医学版), 2017, 43(02): 271-275.
[15]	麦莉, 韦建瑞, 华兴. IRF5基因慢病毒表达载体的构建及其在巨噬细胞RAW264.7中的表达[J]. 吉林大学学报(医学版), 2016, 42(03): 452-456.